Protos safety reviewed by TGA

The TGA has commenced a safety review of the osteoporosis drug strontium ranelate (Protos) following a move by  European drug regulators to ban the drug because of its cardiovascular risks.

On 4 February the TGA announced that it was undertaking a review of Protos “ to assess the risk of adverse events including cardiovascular events.”

The TGA noted that the European Medicines Agency (EMEA) was also currently